Literature DB >> 11932486

Blood substitute and erythropoietin therapy in a severely injured Jehovah's witness.

Clay Cothren, Ernest E Moore, Patrick J Offner, James B Haenel, Jeffrey L Johnson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11932486     DOI: 10.1056/NEJM200204043461420

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the "Seville Document".

Authors:  Santiago R Leal-Noval; Manuel Muñoz; Marisol Asuero; Enric Contreras; José A García-Erce; Juan V Llau; Victoria Moral; José A Páramo; Manuel Quintana
Journal:  Blood Transfus       Date:  2013-06-17       Impact factor: 3.443

2.  Clinical strategies for supporting the untransfusable hemorrhaging patient.

Authors:  Gavin M Melmed; Meredith E Hulsey; Mike Newhouse; Houston E Holmes; Edward J Mays
Journal:  Proc (Bayl Univ Med Cent)       Date:  2009-10

3.  The USA Multicenter Prehosptial Hemoglobin-based Oxygen Carrier Resuscitation Trial: scientific rationale, study design, and results.

Authors:  Ernest E Moore; Jeffrey L Johnson; Frederick A Moore; Hunter B Moore
Journal:  Crit Care Clin       Date:  2009-04       Impact factor: 3.598

Review 4.  Surgical management in treatment of Jehovah's witness in trauma surgery in Indian subcontinent.

Authors:  Renu Kumari
Journal:  J Emerg Trauma Shock       Date:  2014-07

5.  Results of open heart surgery in Jehovah's Witness patients. Single centre experience.

Authors:  Andrzej Juraszek; Piotr Kołsut; Jarosław Szymański; Jarosław Kuriata; Krzysztof Kuśmierski; Ewa Sitkowska-Rysiak; Małgorzata Jasińska; Mariusz Kuśmierczyk
Journal:  Kardiochir Torakochirurgia Pol       Date:  2017-09-30

Review 6.  Preoperative recombinant human erythropoietin in anemic surgical patients.

Authors:  Terri G Monk
Journal:  Crit Care       Date:  2004-06-14       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.